SCHEMBL4675745

SCHEMBL4675745

COc1ccc(Cc2ccc(C(=O)C=C(O)c3nn[nH]n3)o2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
KMT2A Q03164 2/20 0.38
MAPK8 P45983 1/20 0.37
MAPK10 P53779 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 2/20 0.36
POLB P06746 1/20 0.36
ERCC5 P28715 1/20 0.35
FEN1 P39748 1/20 0.35
TSHR P16473 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673269 0.88 ALDH1A1 (0.40) ALDH1A1HPGDLMNATP53HTT
SCHEMBL4671110 0.88 CES1 (0.43) ALDH1A1HPGDERCC5FEN1
SCHEMBL4673268 0.86 XDH (0.40) LMNAKMT2AHTTERCC5FEN1
SCHEMBL4674475 0.86 CES1 (0.34) ALDH1A1HTTERCC5FEN1
SCHEMBL4671648 0.86 CES1 (0.34) LMNATP53CYP1A2CYP2C9CYP2C19
SCHEMBL4677016 0.86 CES1 (0.34) LMNAHTTERCC5FEN1TSHR
SCHEMBL4675232 0.84 ALDH1A1 (0.44) ALDH1A1HPGDLMNATP53KMT2A
SCHEMBL4673591 0.84 MAPK8 (0.37) ALDH1A1HPGDMAPK8MAPK10CYP2C9
SCHEMBL4678110 0.83 KDM5A (0.36) MAPK8MAPK10CYP2C9CYP2C19ERCC5
SCHEMBL4673729 0.81 TP53 (0.42) ALDH1A1HPGDLMNATP53KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885HPGD 2816/4885LMNA 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.